Document Detail


Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known.
MedLine Citation:
PMID:  19555805     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Gamma-hydroxybutyrate (GHB) is an endogenous inhibitory neurotransmitter and anesthetic agent that is being abused as a 'club drug.' Withdrawal symptoms after cessation of GHB use are common and depend on the intensity of use. However, GHB withdrawal syndrome and delirium are unfamiliar to most psychiatrists, probably due to the fact that neither textbooks nor guidelines cover the subject. The GHB withdrawal syndrome may have a fulminant course that progresses to delirium. In those severe cases, admission to a general hospital and involvement of a psychiatrist become necessary. We present two cases of severe GHB withdrawal delirium, provide an overview of the literature and conclude with treatment recommendations.
Authors:
Martijn S van Noorden; Lieselotte C A M van Dongen; Frans G Zitman; Ton A C M Vergouwen
Related Documents :
2008025 - Fetal alcohol syndrome in adolescents and adults.
6544635 - Sinus node dysfunction.
3784775 - Pineal function during ethanol intoxication, dependence, and withdrawal.
15515485 - Austrian syndrome--autopsy report.
8797535 - Progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosupp...
8440285 - A neurophysiological study on the p300 component of event-related potentials in hakim-a...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2008-12-25
Journal Detail:
Title:  General hospital psychiatry     Volume:  31     ISSN:  1873-7714     ISO Abbreviation:  Gen Hosp Psychiatry     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2009-06-26     Completed Date:  2009-07-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905527     Medline TA:  Gen Hosp Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  394-6     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands. msvannoorden@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anti-Anxiety Agents / therapeutic use
Delirium / chemically induced*,  diagnosis,  drug therapy
Diagnosis, Differential
Disease Progression
Female
Half-Life
Hospitals, General
Humans
Lorazepam / therapeutic use
Male
Psychiatry
Sodium Oxybate / metabolism,  poisoning*
Substance Abuse Detection
Substance Withdrawal Syndrome / diagnosis,  drug therapy,  etiology*
Substance-Related Disorders / complications*
Time Factors
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Anxiety Agents; 502-85-2/Sodium Oxybate; 846-49-1/Lorazepam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  alpha/beta-Arteether-induced mania in a predisposed adolescent.
Next Document:  L-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma...